# A Study to Evaluate the Efficacy and Safety of IGIV-C in Symptomatic Subjects With Generalized Myasthenia Gravis

> **NCT02473952** · PHASE2 · COMPLETED · sponsor: **Grifols Therapeutics LLC** · enrollment: 62 (actual)

## Conditions studied

- Myasthenia Gravis, Generalized

## Interventions

- **DRUG:** IGIV-C
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT02473952
- **Lead sponsor:** Grifols Therapeutics LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-08
- **Primary completion:** 2018-01
- **Final completion:** 2018-01
- **Target enrollment:** 62 (ACTUAL)
- **Last updated:** 2019-03-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02473952

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02473952, "A Study to Evaluate the Efficacy and Safety of IGIV-C in Symptomatic Subjects With Generalized Myasthenia Gravis". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02473952. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*